v3.26.3
Segment Information (Details)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2026
USD ($)
Sep. 30, 2025
USD ($)
Sep. 30, 2026
USD ($)
segment
Sep. 30, 2025
USD ($)
Segment Reporting [Line Items]        
Number of operating segments | segment     1  
Number of reportable segments | segment     1  
(Benefit) provision for income taxes $ (64) $ 221 $ 599 $ 1,091
Net loss 129,279 173,443 397,122 593,267
Operating Segments | Reportable Segment        
Segment Reporting [Line Items]        
Preclinical research programs R&D Expense 12,239 16,675 28,518 58,608
R&D personnel expense (excluding share-based compensation) 18,234 20,473 58,667 62,100
R&D Share-based compensation expense 12,066 13,947 42,524 62,291
G&A personnel expense (excluding share-based compensation) 5,819 6,276 17,039 18,755
G&A Share-based compensation expense 6,558 7,588 23,550 33,118
Other segment items 17,009 21,291 47,200 58,950
Non-operating expense (income) 2,923 3,840 14,776 (10,468)
(Benefit) provision for income taxes (64) 221 599 1,091
Net loss 129,279 173,443 397,122 593,267
Operating Segments | BHV-4157 (Troriluzole) | Reportable Segment        
Segment Reporting [Line Items]        
Direct R&D program expense 1,300 10,769 15,926 38,802
Operating Segments | BHV-2000 (Taldefgrobep Alfa) | Reportable Segment        
Segment Reporting [Line Items]        
Direct R&D program expense 6,354 4,489 21,417 18,719
Operating Segments | BHV-7000 & BHV-7010 (Kv7) | Reportable Segment        
Segment Reporting [Line Items]        
Direct R&D program expense 19,295 29,671 52,873 92,415
Operating Segments | BHV-2100 & BHV-2110 (TRPM3 Antagonist) | Reportable Segment        
Segment Reporting [Line Items]        
Direct R&D program expense (1,178) 2,720 (1,708) 26,314
Operating Segments | BHV-8000 (TYK2/JAK1) | Reportable Segment        
Segment Reporting [Line Items]        
Direct R&D program expense 4,208 4,134 13,520 29,722
Operating Segments | BHV-1300 (IgG Degrader) | Reportable Segment        
Segment Reporting [Line Items]        
Direct R&D program expense 9,818 8,628 20,821 28,980
Operating Segments | BHV-1310 (IgG Degrader) | Reportable Segment        
Segment Reporting [Line Items]        
Direct R&D program expense (149) 369 (168) 5,055
Operating Segments | BHV-1400 (IgA Degrader) | Reportable Segment        
Segment Reporting [Line Items]        
Direct R&D program expense 10,067 8,049 26,913 19,646
Operating Segments | BHV-1600 (β1-AR AAB Degrader) | Reportable Segment        
Segment Reporting [Line Items]        
Direct R&D program expense 29 1,977 (70) 6,786
Operating Segments | BHV-1510 (TROP-2) | Reportable Segment        
Segment Reporting [Line Items]        
Direct R&D program expense 2,166 9,327 8,668 19,200
Operating Segments | BHV-1530 (FGFR3) | Reportable Segment        
Segment Reporting [Line Items]        
Direct R&D program expense 2,576 2,437 5,985 21,006
Operating Segments | Other R&D program expense | Reportable Segment        
Segment Reporting [Line Items]        
Direct R&D program expense 9 562 72 2,177
Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment        
Segment Reporting [Line Items]        
Net loss $ 0 $ 0 $ 0 $ 0